EGFR and colorectal carcinoma: The recent conception of anti‐EGFR therapy rechallenge implied the mechanism of resistance or sensitivity to anti‐EGFR drugs in the same patient, as the proportions of RAS WT clones and RAS‐mutant clones in CRC might be changed dynamically during the treatment period.34, 37